| Autor: |
Lupia T; Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy., Corcione S; Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.; School of Medicine, Tufts University, Boston, MA 02111, USA., Fornari V; Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy., Rizzello B; Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy., Bosio R; Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy., Brusa MT; Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy., De Rosa FG; Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy.; Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy. |
| Abstrakt: |
The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for Leishmania infantum infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1-5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted-without recurrence in the follow-up. |
